Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
Jupiter Neurosciences, Inc. announced the initiation of patient enrollment in its Phase 2a RESET clinical trial evaluating JOTROL™, an investigational oral drug candidate targeting Parkinson's Disease. The trial aims to explore JOTROL™'s potential to modify disease progression by addressing underlying neurodegenerative mechanisms. Parkinson's Disea…